Peptide Tools to Study HCMV

About Human Cytomegalovirus

HCMV or HHV-5 belongs to the family of Herpesviridae and is known to establish latency in leukocytes. At least 40% of adults worldwide have been exposed to HCMV. Whereas it is typically unnoticed in healthy individuals, HCMV infection can become life-threatening for high-risk groups such as pre- and postnatal infants or immunocompromised individuals e.g HIV-infected patients and organ transplant recipients. Therefore, these individuals require regular immune monitoring to detect acute HCMV infections.

HCMV in Research

Studies in humans and animal models have demonstrated a critical role for both CD4+ and CD8+ T-cell immunity in limiting viral replication and preventing the clinical manifestations of progressive infection. Many studies focus on pp65 for general immune monitoring. However, other antigens can be immune relevant and are often investigated in HCMV vaccine development. Furthermore, HCMV specific humoral immune responses have been reported and correlated to viral load.

JPT's Peptide Tools to Study HCMV

Cellular Immune Response Profiling

JPT offers tailored custom peptides, peptide libraries and peptide pools for HCMV research. We provide knowledgeable support, high quality, flexible and innovative formats combined with expert know-how to bring forward your research project.

-> PepMix™ Peptide Pools

Immune monitoring of high-risk patients
Qualification of immunodominant antigens
Validating clinical T-cell assays
PepMix™ Collection HCMV: 19 different antigens
HCMV PepMix™ Peptide Pools: Individual peptide pools for IE-1, IE-2, pp65, UL28, UL32, UL36, UL40, UL48, UL55, UL82, UL86, UL94, UL99, UL103, UL151, UL153, US3, US24, US29 and US32
Tailored HCMV PepMix™ Peptide Pools tailored for your specific needs!

-> PepTrack™ Peptide Libraries

T-cell assays
High-throughput T-cell epitope discovery
Monitoring of cellular immune response
Clinical trials

-> Custom Peptide Synthesis

We are the experts for peptide synthesis with highest quality optimized for many applications. Our peptide synthesis service has a very high success rate (over 99%) as we optimize the appropriate peptide synthesis method for each peptide.

If you would like to order a quality peptide synthesis using regulated processes, choose JPT!

Humoral Immune Response Profiling

-> PepStar™ Peptide Microarrays

Immune monitoring of humoral responses
Profiling of HCMV specific samples or antibodies
Evaluation of co-infection
Detection of epitopes and epitope spreading
Peptide microarrays for IE-1, IE-2, pp65, UL28, UL32, UL36, UL40, UL48, UL55, UL82, UL86, UL94, UL99, UL103, UL151, UL153, US3, US24, US29 and US32
Antigen Collection with all of the above on one microarray
Tailored PepStar™ Peptide Microarrays, you define content and layout

-> Peptide ELISA

In addition to high-content peptide microarrays, JPT offers the development of peptide based enzyme-linked immunosorbent assays (ELISA). This common analytical and highly sensitive immunological assay is well established for proteins but requires detailed experimental know-how for peptides. Peptide ELISA is offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays.

Clinical Peptides

-> Clinical Peptides

JPT’s Clinical Peptides product lines Clinical Grade and ISO Plus are produced in production environments that are regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.

References

Wnt activation promotes memory T cell polyfunctionality via epigenetic regulator PRMT1
Bo-Yi Sung et al., Journal of Clinical Investigation (2022) - PMID: 35040433
Products used: PepMix™ HCMVA (pp65)
Bystander CD4+ T cells infiltrate human tumors and are phenotypically distinct
Shamin Li et al., OncoImmunology (2022) - PMID: n.a.
Products used: PepMix™ HCMVA (pp65)
Evaluation of overcoming Limited migration and Enhancing Cytomegalovirus-specific dendritic cell Vaccines with Adjuvant TEtanus pre-conditioning in patients with newlydiagnosed glioblastoma
Randazzo et al., Clinical Trials (2022)
Product used: PepMix™ HCMVA (pp65)
Tracking Dye‐Independent Approach to Identify and Isolate In Vitro Expanded T Cells
Elias et al, Journal of Quantitative Cell Science (2019)
A Novel Simplified Method of Generating Cytomegalovirus-Specific Cytokine-Induced Killer Cells of High Specificity and Superior Potency with GMP Compliance
Luah et al, Clinical Immunology (2019)

Prospective Assessment of CMV Immunity in High-Risk Donor Seropositive (D+) Recipient Seronegative (R-) Liver Transplant Recipients Receiving Either Preemptive Therapy or Prophylaxis
Limaye et al, The Journal of Infectious Diseases (2019)
Comprehensive Evaluation of the Expressed CD8+ T Cell Epitope Space Using High-Throughput Epitope Mapping
Lehmann et al, T Cell Biology (2019)
Phenotypic and Functional Differences Between HHV-6 and HCMV Specific T-Cells
Fastenackels et al, Journal of Virology (2019)
Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay
Cassaniti et al, Journal of Immunology Research (2019)
Human Cytomegalovirus Expands a CD8+ T Cell Population With Loss of BCL11B Expression and Gain of NK Cell Identity
Rosa Sottile et al., Sci Immunology, (2021)
Human Cytomegalovirus and Epstein-Barr Virus Specific Immunity in Patients With Ulcerative Colitis
Rachele Ciccocioppo et al., Clinical and Experimental Medicine, (2021)

More references

Testimonials

“I have been collaborating with JPT for several years. Their unique peptide library technologies and knowledge of specific peptide requirements for T-cell assays made them a valuable, long-termpartner in our efforts to develop novel adoptive immunotherapy approaches to prevent and treat viral infections post-transplant as well as for the treatment of virus and non virus-associated malignancies. Furthermore, their reagents allow us to precisely monitor and track specific T-cell populations post-infusion.”

Ann M. Leen, PhD, Baylor College of Medicine, Center for Cell andGene Therapy, Houston, USA

“Over the past five years my research team has been active in the development of species-specific peptide arrays. Our ability to advance this technology into new research areas has been dependent on working with the highest quality of arrays. In this regard, JPT’s commitment to excellence has been a critical foundation for the success of our research program. I have been consistently impressed with their customer service, technical expertise and professionalism. When it comes to peptide work there are no other options for our group… JPT is the best.”

Scott Napper, PhD, Vaccine and Infectious Disease Organization (VIDO), University of Saskatchewan, Canada

More testimonials